Company Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer.
The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.
It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development.
The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
| Country | GB |
| IPO Date | Jun 22, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 463 |
| CEO | Dr. Christian Martin Itin Ph.D. |
Contact Details
Address: The MediaWorks London, GB | |
| Website | https://www.autolus.com |
Stock Details
| Ticker Symbol | AUTL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001730463 |
| CUSIP Number | 05280R100 |
| ISIN Number | US05280R1005 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Christian Martin Itin Ph.D. | Chief Executive Officer & Director |
| Christopher Vann | Senior Vice President & Chief Operating Officer |
| Robert F. Dolski | Senior Vice President & Chief Financial Officer |
| Alex Driggs | Senior Vice President of Legal Affairs & General Counsel and Secretary |
| Alexander Swan | Senior Vice President & Chief Human Resources Officer |
| Brent Rice | Senior Vice President, Chief Commercial Officer & Site Head of US |
| David Brochu | Senior Vice President & Chief Technical Officer |
| Dr. Chris Williams | Senior Vice President & Chief Business Development Officer |
| Dr. Martin Pule M.D., MBBS | Founder, Senior Vice President & Chief Scientific Officer |
| Olivia Manser | Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | S-8 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 25, 2024 | SC 13D/A | [Amend] Filing |